![]() ICT: What is the next step in the process? Cefiderocol was used as a targeted treatment for documented infections or salvage treatment in approximately 90% of patients and as monotherapy in 41% of patients.6 Fetroja achieved clinical cure in 60% of patients, and 76% were alive within 30 days of starting treatment. High levels of organ support were required in these patients, with 45% receiving mechanical ventilation and 30% requiring vasopressor support. The patients had a respiratory infection and bacteremia as the most common infections. Fetroja was initiated for a documented pathogen in the majority of cases (77%) and as monotherapy in 57% of patients.5Īlso in the study were 98 patients with Acinetobacter baumannii infections (71 from the US and 27 from the EU). The interim results show that cefiderocol achieved clinical cure in 65% of patients, and 81% were alive within 30 days of starting cefiderocol treatment. Approximately 93% of patients had comorbidities nearly half received mechanical ventilation and over a third received vasopressor support. Among these patients, the primary sources of gram-negative infection were respiratory tract infections and bloodstream infections with or without another infection site. SP: The study includes 194 patients with Pseudomonas aeruginosa infections treated with cefiderocol (123 from the US and 71 from the EU). ICT: Please give ICT readers the study details. The WHO has classified certain gram-negative pathogens (including Pseudomonas and Acinetobacter) as the most critical group in need of new antibiotic treatment, given that they are resistant to multiple drugs, including carbapenems.4 In many cases, carbapenems are used as a last resort, highlighting the importance of developing antibiotics for carbapenem-resistant gram-negative bacterial infections. SP: The World Health Organization (WHO) states that bacterial antibiotic resistance is one of the biggest threats to global health.1 In the U.S., almost 3 million antibiotic-resistant infections occur yearly, and more than 35,000 people die.2 To add to this urgency, a WHO analysis presented at ECCMID found that there are not enough new antibiotics in development, especially those that target Acinetobacter baumannii and Pseudomonas aeruginosa.3 ICT: Why is finding an antibiotic for Carbapenem-resistant gram-negative bacterial infections significant? The interim analysis presented at ECCMID demonstrated that cefiderocol achieved clinical cure in 65% and 60% of patients with Pseudomonas aeruginosa and Acinetobacter baumannii infections, respectively, the majority of whom were severely ill with comorbidities. Included in the announcement were interim results from PROVE (Retros pective Cefide rocol Chart Re vi ew), an ongoing international, retrospective study aiming to assess real-world outcomes and safety of Fetroja (cefiderocol) in hospitalized adult patients with gram-negative bacterial infections across the European Union and United States sites. Simon Portsmouth, MBChB, MD, FRCP: Shionogi announced key data for Fetroja (cefiderocol), an innovative siderophore cephalosporin, including new real-world evidence demonstrating its efficacy against some of the most difficult-to-treat gram-negative bacterial infections. ICT: What was the announcement made at ECCMID? Simon Portsmouth, MBChB, MD, FRCP, head of clinical development, Shionogi Inc, answered questions from Infection Control Today® ( ICT®) about the announcement made by the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) on behalf of Shionogi on April 17, 2023, from Copenhagen, Denmark. Recently, an announcement was made at a European infectious disease conference about a antibiotic for Pseudomonas aeruginosa and Acinetobacter baumannii infections. Medical professionals know the critical need for developing new antibiotics, particularly for gram-negative bacterial infections.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |